#USA #San Francisco #Securities Class Action #FTC Lawsuit #Hims

Hims & Hers Health in Legal Turmoil

Hims & Hers Health, Inc. (NYSE: HIMS), a prominent player in the telehealth sector, is currently navigating turbulent waters following significant legal allegations. The company, along with certain executives, is facing a securities class action lawsuit as a direct consequence of a recent Federal Trade Commission (FTC) complaint. This legal action has caused a notable decline in the company's stock value, leading to concerns among investors.

Background of the Case

On October 1, 2026, Hims & Hers faced mounting pressures when the FTC, alongside co-plaintiffs from the State of Utah and Los Angeles County in California, leveled accusations of serious misconduct against the company. The crux of the lawsuit revolves around claims that Hims & Hers engaged in deceptive practices regarding the sharing of sensitive health information and improper billing practices that violate consumer protection laws.

Law firm Hagens Berman, which is spearheading the class action suit, encourages investors adversely affected by recent stock price drops to join the lawsuit. According to reports, the significant drop occurred on July 29, 2026, when Hims & Hers shares plummeted by over 14%, resulting in a loss of nearly $1 billion in market capitalization in a singular instance.

Key Allegations by the FTC

The FTC's allegations detail several serious offenses:

1. Improper Data Sharing: Despite marketing campaigns that emphasize privacy and user data protection, the complaint asserts that Hims & Hers shared confidential user medical conditions and health data with third-party advertising firms, including major platforms like Meta (Facebook) and Snap. This was allegedly done using covert methods such as tracking pixels and customer list matching, which contravenes users' trust in the company's integrity regarding their health data.

2. Subscription Billing Issues: Heightened scrutiny arises from Hims & Hers' enrollment process for recurring subscriptions. The FTC claims that customers were billed for prescriptions shortly after submitting intake forms, prior to any consultations with medical professionals. This practice potentially violates the Restore Online Shoppers' Confidence Act (ROSCA) as consumers were not adequately informed about these recurring charges and faced obstacles when attempting to cancel their subscriptions.

Market Reaction

The stock market's immediate reaction was swift and harsh, with share prices dropping significantly following the announcement of the allegations. Analysts and investors are now evaluating whether Hims & Hers may have misled stakeholders about its business practices, including the sustainability of its internal controls and the potential financial repercussions stemming from these serious legal challenges.

Next Steps for Investors

For investors affected by the stock market crash, Hagens Berman is actively soliciting claims from those who have incurred substantial losses during the class period defined as from August 4, 2025, to July 29, 2026. The lead plaintiff deadline is set for November 2, 2026, and those interested can find more details on Hagens Berman's investigation page.

The complicating factors surrounding this issue include the company's commitment to user privacy juxtaposed with the stark allegations from the FTC, which could continue to unfold in the coming months. Investors, industry analysts, and the public will be closely watching the ongoing developments as this case highlights significant issues within the telehealth industry related to data security and consumer rights.

Furthermore, whistleblowers with non-public information regarding Hims & Hers may also participate in the SEC Whistleblower program which allows for potential rewards for providing original insights about the company's operational processes.

About Hims & Hers Health

Founded to enhance access to medical care through technology, Hims & Hers focuses on providing online consultations and prescription services for a variety of health issues. However, the fallout from these legal challenges could jeopardize its reputation and disrupt its business model if unresolved satisfactorily.

As more information emerges, stakeholders will be keen to learn how Hims & Hers intends to address these concerns and restore confidence among its investor base and the public at large.